Reported 6,219,323 shares, down 142,000 (2.2%) from the prior quarter.
Reported value 7.2%; share count -2.2% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2024-03-31 | 93949644 |
| 2024-06-30 | 204105244 |
| 2024-09-30 | 240993936 |
| 2024-12-31 | 286633075 |
| 2025-03-31 | 218458005 |
| 2025-06-30 | 224172176 |
| 2025-09-30 | 290627690 |
| 2025-12-31 | 529226699 |
| 2026-03-31 | 647267117 |
| 2026-06-30 | 1191348571 |
| 2026-09-30 | 1276578239 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Reduced | 6,219,323 | -142,000 (-2.2%) | 25.38% | $1,276,578,239 | 2026-11-16 | |
| Q2 2026 | Reduced | 6,361,323 | -294,380 (-4.4%) | 22.31% | $1,191,348,571 | 2026-08-14 | |
| Q1 2026 | Added | 6,655,703 | +11,300 (0.2%) | 13.23% | $647,267,117 | 2026-05-15 | |
| Q4 2025 | Added | 6,644,403 | +421,112 (6.8%) | 13.51% | $529,226,699 | 2026-02-17 | |
| Q3 2025 | Added | 6,223,291 | +130,000 (2.1%) | 8.27% | $290,627,690 | 2025-11-14 | |
| Q2 2025 | Reduced | 6,093,291 | -84,820 (-1.4%) | 9.57% | $224,172,176 | 2025-08-14 | |
| Q1 2025 | Reduced | 6,178,111 | -375,000 (-5.7%) | 10.01% | $218,458,005 | 2025-05-15 | |
| Q4 2024 | Added | 6,553,111 | +1,239,022 (23.3%) | 9.97% | $286,633,075 | 2025-02-14 | |
| Q3 2024 | Added | 5,314,089 | +55,000 (1.0%) | 8.15% | $240,993,936 | 2024-11-14 | |
| Q2 2024 | Added | 5,259,089 | +2,344,114 (80.4%) | 7.81% | $204,105,244 | 2024-08-14 | |
| Q1 2024 | New | 2,914,975 | +2,914,975 (0.0%) | 3.31% | $93,949,644 | 2024-05-15 |
Who else reported the position
825 managers reported REVOLUTION MEDICINES INC for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| FMR LLC | Added | 15,397,714 | +3,197,292 | 0.14% | $3,160,534,467 | 27 qtrs |
| BlackRock Inc | Added | 13,857,324 | +161,534 | 0.04% | $2,844,354,468 | 9 qtrs |
| FARALLON CAPITAL MANAGEMENT LLC | Reduced | 13,418,796 | -132,000 | 11.87% | $2,754,342,067 | 23 qtrs |
| BAKER BROS ADVISORS LP | Reduced | 10,637,318 | -806,039 | 10.38% | $2,183,415,893 | 23 qtrs |
| Darwin Global Management Ltd | Unchanged | 10,629,822 | 0 | 54.66% | $2,181,877,264 | 3 qtrs |
| VANGUARD CAPITAL MANAGEMENT LLC | Added | 9,149,534 | +60,873 | 0.04% | $1,878,033,349 | 3 qtrs |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Reduced | 8,157,073 | -137,782 | 0.08% | $1,674,320,804 | 3 qtrs |
| Nextech Invest Ltd | Unchanged | 7,601,087 | 0 | 69.89% | $1,560,199,118 | 7 qtrs |
| JANUS HENDERSON GROUP PLC | Reduced | 7,573,603 | -2,192,893 | 0.66% | $1,555,023,854 | 1 qtr |
| Paradigm Biocapital Advisors LP This report | Reduced | 6,219,323 | -142,000 | 25.38% | $1,276,578,239 | 11 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- November 16, 2026
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 6,219,323
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.